



Exelgyn sponsored Research Grant in partnership with the International Federation of Professional Abortion and Contraception Associates (FIAPAC)

“Improving the quality of life for women having a medical abortion”

Open call for grant proposals

General Conditions

Sponsor background

Exelgyn is a global pharmaceutical company specialised in women's healthcare. Its mission is to further improve healthcare for women worldwide and giving them more autonomy. Since Mifegyne® was launched in 1988, twenty five years ago, Exelgyn has been strongly committed to medical termination of pregnancy and continues striving to ensure women worldwide have access to this safe and effective birth control method. Mifegyne® is approved in more than thirty countries, which has enabled millions of women to terminate their unwanted pregnancy safely and effectively.

Exelgyn is committed to support both healthcare professionals and women throughout each step of a medical termination of pregnancy. Driven by innovation, Exelgyn is committed to research to further improve the treatment process and give women more autonomy.

FIAPAC endorsement

FIAPAC is an international federation of professional abortion and contraception associates whose aims are:

- Freedom for all women to decide whether to remain pregnant or not.
- Providing women with access to the best medical techniques available, when and if they opt for abortion.

- Providing women with psychological and/or social support relating to abortion - where necessary and appropriate.
- Supporting women and men in informed choices concerning contraception.
- Maintaining the highest possible standards in abortion practice and providing contraception, without commercial intent.

FIAPAC are grateful to Exelgyn for this independent research grant that will support the successful member(s) in conducting research in a field that has very limited funding available.

Objective and scope

The objective of this grant is to encourage clinical research and best practice in the management of Medical Termination of Pregnancy (MToP). **The project must comply with the local Summary of Product Characteristics of Mifegyne® and the European Medicines Agency recommendations.**

This research grant aims to promote clinical research that improves the quality of life and the autonomy for women before, during and after a medical termination of pregnancy. This includes but is not limited to:

- Pain associated with first trimester MToP
- Economic aspects of first trimester MToP vs. Surgical Termination of Pregnancy (SToP)
- Increasing the autonomy of women during the process
- Giving the option of home use of misoprostol
- Giving the option of home follow-up (not taking into account the protocol used)
- Medical mid-trimester abortion for medical reasons

Animal research and retrospective analyses on data older than 5 years will not be taken into consideration.

The application must be presented by a single project leader.

Amount

This grant includes financial assistance amounting to a total of 10 000 euros and professional medical writing assistance for English manuscript preparation. This manuscript will be submitted to an international, peer reviewed journal.

The Exelgyn/FIAPAC grant committee may decide to award this sum either in total to fund one project, or separately for two projects.

The award will be paid to an organisation (private, public, research, hospital). It is the beneficiary's responsibility to declare the amount received according to local employment and fiscal regulations.

Candidates

This grant is open to **European** (including overseas territories) Healthcare Professionals involved in MToP such as gynaecologists, GPs or midwives either registered or in training. They should be paid-up members of FIAPAC.

Candidature

Each candidate must provide a complete dossier containing the following items:

- A current curriculum vitae (in English) - max 2 sides of A4
- A letter certifying senior staff agreement, if appropriate
- A filled-in grant application form (see template)

By submitting this application, the applicant agrees to follow the below rules:

- Inform the Exelgyn/FIAPAC Grant Committee Board of all other financial resources, either applied for or obtained.
- Present the research results at the 2018 FIAPAC congress.
- Inform the sponsor of the project's progress by means of written interim reports every 6 months.
- Inform the sponsor and Scientific Board of the final results before external communication.
- Declare all support provided by Exelgyn/FIAPAC in any communication or publication.
- Provide a complete budget at the end of the study.

Exelgyn/FIAPAC Grant Committee Board

The Exelgyn/FIAPAC Grant Committee Board is composed of:

- Christian Fiala (Vienna, Austria)
- Aubert Agostini (Marseille, France)
- Teresa Bombas (Porto, Portugal)
- Sharon Cameron (Edinburgh, United Kingdom)
- Kristina Gemzell (Stockholm, Sweden)
- Roberto Lertxundi (Bilbao, Spain)
- Marek Lubusky (Praha, Czech Republic)
- Mirella Parachini (Roma, Italy)
- Helene Herman-Demars (for Exelgyn, France)

In case of project submitted by a fellow working together with one member of this board, the member of the board will not participate in the discussion regarding this project.

The eligibility and the awards are determined at the sole discretion of the Exelgyn/FIAPAC Grant Committee Board. All decisions made by the Exelgyn/FIAPAC Grant Committee Board are final and are not subject to appeal. No reason for failure to award will be given.

Submission

- The applications must be sent in English by e-mail to fiapacgrant@exelgyn.com
- All applications must be received by end of March 2016. A reception of email act as proof of reception.

Awarding the grant

- The Exelgyn/FIAPAC Grant Committee Board will select the beneficiary(ies) according to the quality and originality of the research proposal.
- The beneficiary(ies) will be informed by a Exelgyn/FIAPAC Grant Committee Board representative in June 2016 at the latest. An agreement will be sent to the person in charge of the project. This document will specify the amount and the terms of payment as well as the conditions that need to be fulfilled to receive the grant (expenses proofs, activity reports and evaluation). The notification letters will be sent by e-mail to "the follow-up address" indicated in the file.
- The selected project(s) will be published on the FIAPAC website, June 2016.
- The project will be awarded during the FIAPAC congress in October 2016.

Award deferral

In the event where there is an insufficient number of applicants, the committee and the organiser reserve the right to either defer the final application date, or defer this call for grants to a later date altogether.